Showing results (591-600 of 868) with videos related to
Sort By:
Pageof 87
Thrombosis and Haemostasis|January 10, 2009
Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generationSamira B Jeimy, Nola Fuller, Subia Tasneem, et al.The Canadian Journal of Cardiology|April 11, 2016
A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk ScoreShamir R Mehta, John W Eikelboom, Purnima Rao-Melacini, et al.Circulation|July 4, 2018
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialOphelia Q P Yin, Elliott M Antman, Eugene Braunwald, et al.Journal of Thrombosis and Haemostasis : JTH|July 19, 2024
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTHJerrold H Levy, Joseph R Shaw, Lana A Castellucci, et al.Blood Advances|June 7, 2019
Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasisAngela C Weyand, Steve J Grzegorski, Megan S Rost, et al.Thrombosis Research|June 5, 2013
Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patientsMark van Geffen, Natascha C J Mathijssen, Pål A Holme, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 20, 2025
Procoagulant imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes. Key role of factor VIIIRosa Lombardi, Roberta Forlano, Gabriele Maffi, et al.Blood Transfusion = Trasfusione Del Sangue|February 13, 2019
A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand diseaseFlora Peyvandi, Giancarlo Castaman, Paolo Gresele, et al.Blood Advances|April 9, 2024
Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohortShermarke Hassan, Guido Baselli, Luca Mollica, et al.Haematologica|July 2, 2026
Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovecVincenzo La Mura, Niccolò Bitto, Alessandro Ciavarella, et al.Pageof 87